Previous Article | Next Article ![]()
Molecular and Cellular Biology, July 2000, p. 4859-4869, Vol. 20, No. 13
Department of Microbiology and Immunology,
Nashville, Tennessee
Received 10 February 2000/Accepted 5 April 2000
Protein arginine N-methyltransferases have been
implicated in a variety of processes, including cell proliferation,
signal transduction, and protein trafficking. In this study, we have characterized essentially a null mutation induced by
insertion of the U3 Methylation of arginine
residues is one of many covalent modifications of eukaryotic proteins
that occur concomitant with or shortly following translation. Two types
of protein arginine methyltransferases have been
classified according to their substrate specificity and reaction
products (reviewed in reference 11). Type I
enzymes catalyze the formation of
NG-monomethylarginine and
asymmetric
NG,NG-dimethylarginine,
while type II enzymes catalyze the formation of
NG-monomethylarginine and symmetric
NG,N'G-dimethylarginine.
Most substrates for type I enzymes bind nucleic acid, usually RNA.
These include heterogeneous nuclear RNA binding proteins (hnRNPs),
which collectively contain 65% of the nuclear asymmetric
dimethylarginine, as well as fibrillarin and
nucleolin (19-21). The only known physiological substrate
of symmetric (type II) arginine methyltransferase is myelin
basic protein, a major protein component of the myelin sheath.
Genes encoding rat (PRMT1), human (HRMT1L2), and
yeast (RMT1) type I enzymes have been characterized
(12, 13, 17, 29). The mammalian genes appear to be
ubiquitously expressed in all tissues (17, 29, 32). The
yeast enzyme, which is not required for cell viability, accounts for
over 85% of the protein dimethylarginine in the
cell (12).
Type I enzymes have been implicated in a variety of processes,
including cell growth control, signal transduction, and protein trafficking, but the biochemical and biological functions of
arginine methylation have not been established. The enzymes
preferentially methylate motifs rich in arginine and glycine
(RGG boxes), a common feature of the RNA binding domains of hnRNPs
(20). Arginine-methylated hnRNP A1 (24), but not
Hrp1p (33), has lower affinity for RNA than the native
protein, suggesting a potential mechanism for modulation of
protein-RNA interactions. Levels of protein methylarginine may change in response to
extracellular stimuli under circumstances in which biological
responses are also suppressed by methyltransferase inhibitors.
These include nerve growth factor-induced neurite outgrowth in PC12
cells (6) and mitogenic responses of
lipopolysaccharide-treated B cells (16).
Interactions between the PRMT1 enzyme and potential signaling
components have also emerged from yeast two-hybrid screens. The
immediate-early gene product TIS21 (BTG2) and the leukemia-associated gene product BTG1 interact with PRMT1 and can modulate its enzymatic activity in vitro (17). TIS21 and BTG1 both belong to a
family of mitogen-induced proteins implicated in negative regulation of
the cell cycle. PRMT1 also binds to the cytoplasmic domain of the
IFNAR1 chain of the alpha beta interferon receptor, while growth-inhibitory effects of interferon were suppressed by antisense oligonucleotides directed against the methyltransferase (1). Finally, a novel arginine methyltransferase (CARM1) associates with p160 coactivators and serves as a secondary coactivator of nuclear
hormone receptors (4).
Other studies have identified a role for arginine methylation
in protein trafficking. Shuttling of the yeast hnRNP-related proteins
Np13p and Hrp1p between the nucleus and cytoplasm requires methylation
by the Hmt1p methyltransferase (30). The human enzyme complements the shuttling defect, suggesting functional conservation between the two enzymes. Nuclear translocation of the large form of
basic fibroblast growth factor may also depend on arginine methylation (23). In the presence of a methyltransferase
inhibitor, basic fibroblast growth factor was not methylated and the
protein did not localize to the nucleus.
The prevalence of
NG,NG-dimethylarginine
in RNA binding proteins and conservation among protein arginine
N-methyltransferases underscore the potential
biological importance of this posttranslational modification. However, a major issue arguing against a dynamic role for
the type I enzymes in cell regulation concerns the possibility that
arginine methylation is both constitutive and irreversible. While most substrates have not been characterized, some are known to
exist only in a fully methylated state (18, 19). Moreover, no demethylase capable of removing dimethylarginine
residues has been identified (11) and in the case of
histones, turnover of dimethylarginine accompanies
protein degradation (3).
Efforts to understand the biochemical function of mammalian
arginine methyltransferases are complicated by several factors, including the existence of multiple enzymes and the fact that methyltransferase inhibitors nonspecifically target multiple
processes in which S-adenosylmethionine serves as a
methyl donor. In yeast, functional studies of arginine
methylation have benefited greatly from genetic approaches that have
led to the isolation of cells deficient in the enzyme. In principle,
gene targeting strategies could be used for similar studies of the
mammalian enzymes, assuming that the proteins are not required for cell viability.
The present study characterized a recessive early embryonically lethal
mutation in a gene encoding the mouse ortholog of the human protein
arginine N-methyltransferase 1 enzyme. The mutation was originally induced by gene entrapment in mouse embryonic stem (ES)
cells and was selected during an in vitro screen for mutations in
developmentally regulated genes (28). We now show that the enzyme is essential for early development, is a major source of arginine methyltransferase activity in ES cells, and yet
is not required for cell viability. While proteins from mutant cells were significantly hypomethylated, most potential substrates in wild-type cells appeared to be blocked by prior methylation. The availability of Prmt1-deficient cells is expected to assist efforts to
understand the function of this enzyme in normal cellular metabolism.
Analysis of mutant and wild-type embryos. (i) Histology.
Decidual swellings containing embryonic day 6.5 (E6.5) and E7.5 embryos
were dissected in ice-cold phosphate-buffered saline (PBS), fixed in
PBS containing 4% paraformaldehyde and 0.2% glutaraldehyde overnight
at 4°C, dehydrated in a graded ethanol series, cleared in xylene,
embedded in Paraplast X-tra (Polysciences), and sectioned. Serial
sections (7 µm) were collected on slides, stained with hematoxylin
and eosin (Sigma), and mounted in Permount (Fisher Scientific).
(ii) Genotype analysis.
Offspring bearing the 7.4.2 provirus were identified by Southern blot hybridization to a 1.3-kb
StuI fragment that contained genomic sequences of the
Prmt1 gene. E3.5 to E8.5 embryos were genotyped by PCR using
a mixture of three primers, i.e., forward 7.4.2#1
(5'ATATCCTTTTGTGAGACCCC), reverse 7.4.2#2
(5'GGAAGGGCTCTGTCCTAA), and reverse lacZ#3
(5'CCTCTTCGCTATTACGCCAG). Each 25-µl PCR mixture contained
10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 200 µM
each deoxyribonucleoside triphosphate, 1.25 U of Amplitaq (Perkin-Elmer Cetus), and each primer at 0.2 µM. Reactions proceeded through 40 cycles of denaturation (95°C for 1 min), primer annealing (55°C for
1 min), and primer extension (72°C for 2 min), followed by a final
10-min extension at 72°C. The resulting PCR products were resolved by
1.2% agarose gel electrophoresis and visualized by UV light after
staining with ethidium bromide. DNAs from mice and embryos were
isolated as described previously (35).
5'RACE.
Transcribed cellular sequences present in
7.4.2- Isolation of Prmt1 genomic and cDNA clones.
The
189-nt 7.4.2 fusion transcript isolated via 5'RACE was used
to screen an E8.5 mouse cDNA library (9). Two positive clones were identified out of a total of 106 plaques, and
cDNA inserts of 1.1 kb and 600 nt were subcloned into the
EcoRI site of pBluescript KS(
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Arginine N-Methyltransferase 1 Is Required for Early
Postimplantation Mouse Development, but Cells Deficient in the Enzyme
Are Viable


![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Geo gene trap retrovirus into the second intron
of the mouse protein arginine
N-methyltransferase 1 gene (Prmt1). cDNAs encoding two forms of Prmt1 were characterized, and the predicted protein sequences were found to be highly conserved among vertebrates. Expression of the Prmt1-
geo fusion gene was
greatest along the midline of the neural plate and in the forming head
fold from embryonic day 7.5 (E7.5) to E8.5 and in the developing
central nervous system from E8.5 to E13.5. Homozygous mutant
embryos failed to develop beyond E6.5, a phenotype consistent
with a fundamental role in cellular metabolism. However,
Prmt1 was not required for cell viability, as the protein was not
detected in embryonic stem (ES) cell lines established from mutant
blastocysts. Low levels of Prmt1 transcripts (approximately
1% of the wild-type level) were detected as assessed by a quantitative
reverse transcription-PCR assay. Total levels of arginine
N-methyltransferase activity and asymmetric
NG,NG-dimethylarginine
were reduced by 85 and 54%, respectively, while levels of
hypomethylated substrates were increased 15-fold. Prmt1 appears to
be a major type I enzyme in ES cells, and in wild-type cells, most
substrates of the enzyme appear to be maintained in a fully methylated state.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-Galactosidase expression.
E6.5 to E13.5 embryos
were fixed in PBS containing fresh 2% paraformaldehyde and 2%
glutaraldehyde for 30 min at 4°C, rinsed twice for 15 min each time
and once for 1 h in ice-cold PBS, and stained overnight in PBS
containing 0.02% NP-40, 0.01% sodium dodecyl sulfate (SDS), 2 mM
MgCl2, 5 mM K3Fe(CN)6, 5 mM
K4Fe(CN)6, and 1 mg of
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal; Sigma), pH 7.2, per ml. Stained embryos were rinsed in PBS and visualized by dark-field microscopy.
Geo fusion transcripts were cloned by rapid
amplification of cDNA 5' ends (5'RACE) using a 5'RACE kit (Gibco BRL)
and following the manufacturer's instructions. First-strand cDNA was
synthesized using 3 µg of total cellular RNA (5) and 0.2 µM reverse primer lacZ#3 (5'CCTCTTCGCTATTACGCCAG). After removal of the RNA template with RNase H (3.0 U), the cDNA was purified using BRL GlassMax spin cartridges and tailed with dCTP
and terminal deoxynucleotidyltransferase. A 5-µl sample of tailed
cDNA was amplified with 0.2 µM nested primer lacZ#2
(5'CTGCAAGGCGATTAAGTTGGG) and 0.2 µM Bethesda Research
Laboratories anchor primer through 40 cycles of denaturation (95°C
for 1 min) and primer annealing (55°C for 2 min) and extension
(72°C for 3 min) and a 10-min extension at 72°C. The resulting PCR
products were analyzed by Southern blot hybridization using a probe
complementary to the first 20 nucleotides (nt) of the proviral long
terminal repeat (LTR) (5'CCTACAGGTGGGGTCTTTCA). PCR products
were gel purified (QIAquick gel extraction kit; QIAGEN), subcloned into
the pCR plasmid vector (Invitrogen), and sequenced.
) (Stratagene) and sequenced. Subsequently, the 1.1-kb cDNA was used as a probe to rescreen the mouse
E8.5 library and to screen an ES cell cDNA library (provided by B. Rosenberg, Massachusetts Institute of Technology). Altogether, 25 clones were isolated from the two libraries and sequenced.
Fix
II sv129 genomic library using the 189-nt 5'RACE product as a probe.
Five clones contained a 1.3-kb StuI fragment that hybridized
to 5'RACE sequences immediately adjacent to the provirus. The 1.3-kb
fragment was subcloned into the EcoRV site of pBluescript KS(
) (Stratagene) and sequenced.
Northern blotting and RT-PCR.
Total cellular RNA was
isolated from various C57BL/6J mouse tissues (liver, heart, lung,
kidney, ovary, brain, and spleen), whole wild-type embryos, and ES
cells of the D3 line via the method of Chomczynski and Sacchi
(5). A 15-µg sample of each RNA was denatured with
formamide, electrophoretically separated on 1% formaldehyde
agarose gels, transferred to a HyBond-N+ filter (Amersham), and hybridized to [
-32P]dCTP-labeled probes
(10).
Mapping. An interspecific backcross [(C57BL/6J × Mus spretus)F1 × M. spretus] DNA panel from the Jackson Laboratory community resource (26) was used to map the Prmt1 locus. Genomic DNAs from C57BL/6J and M. spretus were digested with various restriction enzymes and blot hybridized to the 1.3-kb Prmt1 genomic probe to detect restriction fragment length polymorphism (RFLP) between the two strains. Filters containing MspI-digested genomic DNAs from the 94 backcrosses and two parental strains (BSS panel) were obtained from the Jackson Laboratory and hybridized to the 1.3-kb Prmt1 genomic probe. Each DNA was scored for the presence of the C57BL/6J allele, and the results were analyzed against the Jackson Laboratory database to determine the position on the existing map.
DNA sequencing. DNA sequencing reactions used the BigDye Terminator Cycle Sequencing Kit (ABI) and were analyzed on a Prism 377 DNA Sequencer. Templates were either subcloned into pBluescript (Stratagene) or sequenced directly from phage DNAs. Primers were either T3 and T7 or oligonucleotide primers corresponding to various regions of Prmt1. DNA sequences were compiled with Sequencher 3.0 software (Gene Codes Corporation), and sequence homology searches were performed using the BLAST algorithm (2).
Isolation of ES cells. ES cells lines were isolated from E3.5 blastocysts as described previously (35) and were maintained on 0.1% gelatinized tissue culture plates in ES cell medium (high-glucose Dulbecco modified Eagle medium [Gibco] supplemented with 15% preselected fetal bovine serum [Hyclone; heat inactivated at 55°C for 30 min], 0.1 mM 2-mercaptoethanol, and 100 mM nonessential amino acids [Gibco]) supplemented with 1,000 U of leukemia inhibitory factor (ESGRO; Gibco) per ml. Cultures were trypsinized every 2 days and replated at a 1:3 ratio with either a feeder layer of gamma-irradiated mouse embryo fibroblasts for maintenance of the cell line or for at least 3 generations without feeder layers for isolation of DNA, RNA, and cell extracts.
Western blotting analysis. Samples (200 µg of protein each) were mixed with an equal volume of 2× Laemmli loading buffer (27), boiled for 5 min, and fractionated by SDS-10% polyacrylamide gel electrophoresis. Proteins were transferred onto PolyScreen polyvinylidene difluoride membrane (NEN Life Sciences) in Tris-glycine buffer (27). Polyclonal serum from rabbits immunized against recombinant rat PRMT1 (32) was diluted 1:3,000 in TBST (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05% Tween 20) containing 5% milk and bound to proteins for 1 h. Membranes were washed three times for 10 min each time in TBST, incubated with a 1:10,000 dilution of peroxidase-conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology, Inc.) in TBST for 30 min, and detected by enhanced chemiluminescence assay (Amersham).
Methyltransferase assays. For protein extraction, cells were harvested at 75% confluency, washed twice, scraped into ice-cold PBS, pelleted, and resuspended in 1 ml (per 10-cm-diameter plate) of ice-cold reaction buffer (50 mM Tris-HCl [pH 7.6], 0.1 mM EDTA, 0.1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride). The cell suspensions were sonicated on ice with two 15-s bursts using a microtip sonicator (XL2015; Heat Systems) at a setting of 4.0 and clarified by centrifugation at 10,000 × g for 30 min, and the supernatant was flash frozen in an ethanol-dry-ice bath. Protein concentrations were determined by a modified Lowry assay (DC Protein Assay; Bio-Rad).
Reactions to measure methyltransferase activity were performed in reaction buffer supplemented with 50 µM S-adenosyl-L-[methyl-3H]methionine (Amersham; adjusted to 5,000 dpm/pmol with unlabeled AdoMet), 100 µM R3 peptide (21), and either wild-type or mutant cell extract. Reactions to measure the methylation status of proteins in cell extracts were performed in reaction buffer containing 50 µM S-adenosyl-L-[methyl-3H]methionine and either equal amounts of wild-type and mutant cell extracts or wild-type cell extract alone. Methylation reaction mixtures contained 140 µg of total protein in 140 µl and were incubated at 36°C. Aliquots (20 µl) were withdrawn at different intervals, added to 20 µl of 2× SDS sample buffer, and heated to 100°C for 5 min to stop the reaction. The samples were diluted into 1 ml of PBS, and the incorporated methyl-3H was determined via a filter binding assay (20).Amino acid analysis. Analysis of methylated arginine derivatives in total cell lysates was performed by the Vanderbilt-Ingram Cancer Center Peptide Sequencing and Amino Acid Analysis Shared Resource. Briefly, samples were hydrolyzed with 6N HCl (110°C for 18 h) in vacuo in a Waters PicoTag apparatus, derivatized by the Waters AccQ Tag amino acid analysis method, and separated on a Waters AccQ Tag C18 column (3.8 by 150 mm) developed with a 1:40 dilution of eluent A (Waters). Methylated arginine standards (NG-monomethylarginine, asymmetric NG,NG-dimethylarginine, and symmetric NG,N'G-dimethylarginine; Sigma) were analyzed under the same conditions, and their elution profiles were compared to the elution profiles of cell protein hydrolysates.
Nucleotide sequence accession numbers. The genomic sequences reported here have been submitted to GenBank and assigned accession no. AF232718 (see Fig. 4B), AF232716, and AF232717 (see Fig. 5).
| |
RESULTS |
|---|
|
|
|---|
Expression of the gene disrupted by the 7.4.2 provirus.
The 7.4.2 mutation was induced by the
U3
GeoSupF retrovirus in mouse ES cells and identified during an in
vitro screen for inserts into developmentally regulated genes. The
provirus expresses a
-galactosidase-neomycin phosphotransferase
fusion protein encoded by transcripts that initiate in the flanking
cellular DNA. The 7.4.2 mutation was chosen for germ line
transmission because expression of the
-galactosidase fusion gene
was induced during differentiation in vitro (28).
Undifferentiated 7.4.2 ES cells stained mostly white but
showed an increase in lacZ expression following
differentiation into embryoid bodies. lacZ expression was
also developmentally regulated in vivo (Fig.
1).
-Galactosidase activity was not
detected in blastocyst stage embryos (E3.5) but was induced in
postimplantation embryos as early as E6.5. At E6.5, diffuse staining
was evident throughout the whole embryonic portion of the egg cylinder,
and by E7.5, staining appeared strongest along the midline of the neural plate and in the forming head fold (Fig. 1A). Diffuse staining was also visible throughout the rest of the neural plate and in the
primitive streak. E8.5 embryos stained mostly in the areas corresponding to the developing central nervous system, including both
the brain and spinal cord regions. Intense staining was visible in the
anterior-most aspect of the developing brain (prosencephalon) and
continued caudally through the mesencephalon, rhombencephalon, and
fusing neural folds (Fig. 1B to D). Neural-tube staining was restricted
to the lateral sides, and the floor plate did not stain at all.
Staining was also apparent in the primitive streak, brachial arches,
notochord, and heart anlage. Again, diffuse staining was visible
throughout the embryos. Between E9.5 and E13.5, this diffuse staining
pattern became even more apparent; however, darker staining was still
visible in the telencephalon, neural tube, heart, and first and second
brachial arches (Fig. 1E). In addition, staining could be seen in the
developing forelimb bud. At all of the developmental stages examined,
X-Gal staining was widespread in the embryo but absent from
extraembryonic tissues, including the yolk sac, extraembryonic ectoderm, and ectoplacental cone.
|
Mice homozygous for the 7.4.2 mutation die in utero. Initial characterization of 48 offspring from intercrosses between 7.4.2 heterozygotes revealed that none of the viable offspring were homozygous for the provirus. Out of 48 offspring genotyped, 34 heterozygotes and 14 wild-type pups were recovered, a ratio of approximately 2.5:1. This situation strongly suggested that the 7.4.2 provirus disrupted a gene essential for murine development and that homozygous embryos die in utero. As 7.4.2 mice have been maintained for over 10 generations, the embryonically lethal phenotype appears to be tightly linked to the provirus.
In order to determine the time of embryonic death, 187 embryos obtained by crossing 7.4.2 heterozygotes were dissected from the uterine decidua between E6.5 and E10.5 and genotyped by PCR (Fig. 2B). Since the sequences flanking the provirus were cloned (see below), wild-type and mutant alleles could be easily distinguished based on the size of the PCR product (Fig. 2A). No homozygous embryos were recovered at E10.5 and E8.5, although a large number of empty resorption sites were observed (between 16 and 30% of the litter). Heterozygous embryos were morphologically indistinguishable from their wild-type littermates. The ratio of wild-type to heterozygous embryos indicated that 7.4.2 homozygotes die before E8.5, accounting for the large proportion of resorption sites. Only one homozygous embryo was recovered at E7.5. This embryo was much smaller than its wild-type and heterozygous littermates and resembled a severely disorganized and degenerated egg cylinder. Two homozygous embryos recovered at E6.5 also displayed an obvious developmental delay in embryonic portions of the embryo, while extraembryonic tissues seemed to develop normally. Other small and partially resorbed embryos dissected at the E6.5 and E7.5 stages were genotyped as heterozygotes. However, this probably reflects contamination of homozygous mutant embryos with maternal tissue, accounting for the lower-than-expected yield of 7.4.2 homozygotes at this stage. Since we were able to recover morphologically normal homozygous mutant blastocysts (E3.5), which were present at the expected ratio, it is likely that embryonic death occurs shortly after implantation (E4.5) but before the onset of gastrulation (E6.5).
|
|
|
Characterization of the gene disrupted by the 7.4.2 provirus.
Transcribed cellular sequences appended to proviral
Geo sequences were cloned by 5'RACE. This exploits the fact
that cell-virus fusion transcripts initiate in the flanking
cellular DNA and terminate at the poly(A) site in the 5'
LTR. The resulting 189-nt 5'RACE product was sequenced (Fig.
4A) and used to probe Northern blots of
cellular RNA from 7.4.2 cells. A single 1.3-kb transcript was detected
(data not shown). The 5' RACE fragment was subsequently used to isolate
cDNAs of the mutated gene and genomic DNA sequences surrounding the
7.4.2 provirus.
|
Geo provirus (Fig. 4C). In addition, no rearrangements were
observed in either the virus or flanking cellular DNA.
The composite cDNA sequence of the gene disrupted by the
7.4.2 provirus is depicted in Fig.
5. Open reading frames of 353 or 371 amino acids are present, depending on the absence or presence of the
54-nt exon. Although the first ATG in the composite cDNA sequence
is in a favorable context for translation initiation, there is no
in-frame upstream stop codon. Comparison of the composite cDNA
sequence to 112 murine and 209 human expressed sequence tags obtained
from the National Center for Biotechnology Information dbEST database
revealed none that extended beyond the 5' end of the composite cDNA
(data not shown). The 54-nt exon was present in 5 out of 13 cDNAs from the E8.5 library but only in 1 of 10 cDNAs from the
ES cell library.
|
The 7.4.2 gene encodes a protein arginine N-methyltransferase. A BLAST search of the nucleic acid databases with the composite 7.4.2 cDNA sequence returned matches with rat (PRMT1), human (HRMT1L2), and yeast (RMT1/HMT1) protein arginine N-methyltransferases. The rat cDNA lacked the 54-nt sequence corresponding to the presumed alternative exon (17). However, this sequence was present in two out of three variants of the human gene (29). The mouse and rat sequences are identical at the protein level, except for the 18-amino-acid segment missing from the rat protein that corresponds to the 54-nt alternative exon. The mouse and human proteins are 95% identical, differing at only two internal positions (E118 to V and H179 to Y) and 10 amino-terminal residues present in the mouse (and rat) protein but absent from human HRMT1L2 (Fig. 5). The mouse protein also shares 45% overall identity with the Saccharomyces cerevisiae RMT1 enzyme (12) and 11% identity with the Escherichia coli L11 methyltransferase (34). This high degree of phylogenetic conservation was especially evident in regions containing consensus methyltransferase motifs (Fig. 5). Based on these sequence comparisons, we concluded that the gene disrupted by the 7.4.2 provirus is the murine ortholog of the rat and human protein arginine N-methyltransferases (PRMT1 and HRMT1L2, respectively). The 7.4.2 gene was provisionally named Prmt1 for mouse arginine N-methyltransferase 1.
Prmt1 is widely expressed in mouse tissues and in
embryos.
The pattern of
-galactosidase expression suggested
that Prmt1 is regulated in a tissue- and/or stage-specific
manner. Analysis of total cellular RNAs from several mouse tissues
(liver, heart, lung, kidney, ovary, brain, and spleen); E8.5, E9.5, and
E11.5 mouse embryos; and the D3 ES cell line by Northern blot
hybridization revealed that Prmt1 encodes a 1.3-kb
transcript present in all of the RNAs examined (Fig.
6A). In general, the transcript seems to
be more abundant in ES cells and embryos than in adult tissues. Prmt1 transcript levels also varied among all of the adult
tissues tested, with the highest expression in the ovaries and uterus and the lowest in the liver. Of the three brain regions examined, only
the cerebellum displayed a slightly higher transcript level.
|
Prmt1 maps to mouse chromosome 7.
The chromosomal
location of the mouse Prmt1 locus was determined by
interspecific backcross analysis using the Jackson Laboratory interspecific backcross panel (C57BL/6JEi × SPRET/Ei)F1 × SPRET/Ei. This mapping panel has
been initially typed for over 450 chromosomal and X-linked loci spread
among the autosomes, as well as the X chromosome, and the resulting
genetic map was anchored to published maps by mapping known loci,
simple sequence length polymorphisms, and loci defined by endogenous
retroviruses. In order to identify a suitable RFLP for use in mapping
studies, C57BL/6JEi and M. spretus genomic DNAs were
digested with a panel of restriction enzymes and analyzed by Southern
blot hybridization using the 1.3-kb Prmt1 probe.
Subsequently, an MspI RFLP was used to map the
Prmt1 locus on mouse chromosome 7 between Fig1 and
D7Bwg0826e (Fig. 7). No known mutation or
disease phenotype is linked to the Prmt1 locus.
|
Isolation of ES cells from mutant blastocysts. In principle, the Prmt1 mutation could be a cell-lethal defect in which mutant embryos persist beyond implantation due to maternal stores of mRNA, enzyme, or methylated substrates. Although most maternal RNA is rapidly degraded following the first cell division, the Prmt1 enzyme or methylated substrates could persist for several days. To determine whether Prmt1 is required for cell viability, we sought to derive a homozygous mutant ES cell line from preimplantation blastocysts. In our experience, ES cell lines are easier to derive from 129sv mice than from the C57BL/6 mice that harbor the 7.4.2 mutation. Therefore, the Prmt1 mutation was crossed for 3 generations into 129sv mice. F3 mice heterozygous for the provirus were interbred, and blastocysts were collected at E3.5 and cultured as described in Materials and Methods. Individual cell lines were established from 9 out of 40 blastocysts, of which 5 were homozygous for the Prmt1 mutation. All mutant cell lines appeared morphologically similar to other ES cell lines and grew with doubling times similar to that of wild-type ES cells (approximately 12 h; data not shown).
Prmt1 is not required for cell viability.
U3 gene
trap vectors were designed to disrupt cellular gene expression by
terminating transcription at one of two poly(A) sites (one in each LTR)
carried by the provirus (14). Previous studies found high
levels of a 4.7-kb
Geo transcript in 7.4.2 cells, approximately the
size expected for Prmt1-
Geo fusion transcripts that
terminate in the 5' LTR. To test whether the 7.4.2 provirus disrupted expression of the Prmt1 gene, homozygous mutant
cell lines (Fig. 8A) were analyzed by
Northern and Western blotting. Transcripts of 1.3 kb were detected in
the wild-type and heterozygous cell lines, but not in the two mutant
cell lines, using Prmt1 cDNA sequences downstream of the
site of provirus integration as a probe (Fig. 8B). Similarly, the Prmt1
protein was detected in extracts from wild-type and heterozygous cells
but not in those from homozygous mutant cells (Fig. 8C). Levels of
Prmt1 transcripts in mutant cells were estimated by RT-PCR
after mixing of different amounts of wild-type RNA with a constant
amount of mutant RNA (Fig. 8D). The PCR signal obtained after mixing of
mutant RNA with a 100-fold dilution of wild-type RNA was clearly
greater than that obtained with mutant RNA alone, whereas the 250-fold dilution did not enhance the amplification of Prmt1
sequences. This suggests that mutant cells express approximately 1% of
the wild-type level of Prmt1 transcripts. We conclude that
the 7.4.2 provirus severely disrupts Prmt1 expression and
that the protein is not required for cell viability.
|
Loss of arginine methyltransferase activity in homozygous
mutant ES cells.
Although Prmt1 is orthologous to the predominant
arginine methyltransferase expressed in mammalian cells, other
enzymes are known to have type 1 activity (32). In addition,
loss of Prmt1 could lead to a compensatory increase in the expression
or activity of other methyltransferases. We therefore examined total
methyltransferase activities in wild-type and Prmt1 mutant cells. As
shown in Fig. 9A,
Prmt1
/
cells expressed approximately eight
times less methyltransferase activity than
Prmt1+/+cells, as assayed with an optimal
synthetic-peptide substrate (21). This reduction is
comparable to the contribution by Prmt1 orthologs to the total
methyltransferase activity in other cell types, as estimated
biochemically (12, 31). Therefore, we conclude that Prmt1 is
the major type I enzyme in ES cells and that loss of Prmt1 activity
does not result in a major compensatory increase in other
methyltransferases.
|
Hypomethylation of cell proteins in Prmt1-deficient
cells.
Mutations in RMT, a type I enzyme of yeast, result in
increased levels of hypomethylated substrates (12).
Therefore, two types of experiments were performed to examine the
methylation status of proteins in Prmt1
/
cells. First, total proteins extracted from
Prmt1
/
and Prmt1+/+
cells were tested for methyl acceptor activity when mixed with wild-type cell extracts. As shown in Fig. 9B, the methyl acceptor activity of total protein isolated from mutant cells was approximately 15 times greater than that observed for proteins from wild-type cells.
The fact that proteins from wild-type cells proved to be such poor
substrates suggests that most potential substrates are blocked by prior
methylation, as has been observed with nucleolin and fibrillarin, which
exist in a fully methylated state developmentally in vivo (18,
19). Second, the methylarginine content of cellular proteins was measured following acid hydrolysis and high-pressure liquid chromatography. As shown in Fig. 9C, total levels of asymmetric dimethylarginine were approximately twofold lower
in Prmt1-deficient cells than in wild-type cells (54% ± 1.5%
reduction based on three independent pairs of samples) whereas levels
of monomethylarginine and symmetric
dimethylarginine were slightly increased.
| |
DISCUSSION |
|---|
|
|
|---|
We previously described methods for using lacZ-based
vectors to screen for mutations in regulated genes (25, 28).
The present study characterized one of these mutant cell lines, termed 7.4.2, generated by an inserted U3
Geo provirus. The 7.4.2 cell line
showed an increase in lacZ expression upon differentiation of ES cells into embryoid bodies (28). We show here that the gene disrupted by the provirus encodes the murine arginine
methyltransferase 1 enzyme (EC 2.1.1.23). Embryos homozygous for the
mutation arrest in development prior to E6.5, indicating that protein
methylation is required for early postimplantation development.
However, cell lines derived from homozygous mutant embryos are viable
despite the fact that Prmt1 enzyme levels and the extent of protein
methylation are significantly reduced.
cDNAs encoding Prmt1 were characterized as part of our analysis of the 7.4.2 mutation. As previously reported for the human gene, Prmt1 transcripts are alternatively spliced to generate coding sequences for proteins of 353 or 371 amino acids. Overall, murine Prmt1 shares 100 and 95% sequence identity with the rat and human proteins, respectively. Phylogenetic conservation of the two proteins suggests that each has a distinct function, possibly related to substrate specificity or regulation of enzyme activity. Finally, Prmt1 was mapped to mouse chromosome 7 in a region syntenic with the region of human chromosome 19q, where the human gene had been previously mapped (29). Neither region is associated with disease loci in mice or humans.
Our analysis of Prmt1 expression confirms earlier reports
describing widespread expression of the orthologous rat and human genes
in all of the tissues examined (17, 29, 32). In addition, all of the tissues examined expressed both spliced forms of the murine
gene. Expression of the inserted
-galactosidase marker was highest
in developing neural structures. This is potentially significant in
light of previous studies showing high levels of methyltransferase
activity in the developing brain that decline after birth
(22). However, homozygous mutant embryos die close to the
time when the Prmt1 gene is first induced, as assessed by
-galactosidase staining, and well before the onset of neural development. As early embryonic death appears to be a common
consequence of mutations disrupting basic cellular processes
(7), the phenotype is consistent with the important role
Prmt1 is thought to play in RNA metabolism. For example, the timing of
embryonic death is similar to that observed with a mutation in
Fug1, which encodes the RAN GTPase-activating protein
(8), and is earlier than that observed with a mutation in
hnRNP C, a highly abundant, ubiquitous constituent of nuclear
riboprotein complexes (35). Both RAN GAP and hnRNP C appear
to function in RNA biogenesis and transport.
By comparing the levels of enzyme activity in extracts from wild-type and Prmt1-deficient cells, we showed that Prmt1 accounts for over 85% of the total arginine methyltransferase activity in ES cells, as assayed using an optimal (21) synthetic RGG substrate. However, Prmt1 is responsible for just over 50% of the normal steady-state levels of NG,NG-dimethylarginine present in cellular proteins. Therefore, other arginine methyltransferases, presumably with different substrate specificities, appear to make significant contributions to the total dimethylarginine content of the cell. Such enzymes could include PRMT3 and HRMT1L1, type I-related enzymes that modify RGG substrates poorly, if at all (29, 32).
The methylation status of cellular proteins was also assessed by testing their capacity to be methylated in vitro. Prmt1, present in wild-type cell extracts, was incubated with proteins isolated from either wild-type or Prmt1-deficient cells in the presence of S-adenosyl-L-methyl-[3H]methionine. While proteins from wild-type cells had negligible acceptor activity, proteins from Prmt1-deficient cells were significantly hypomethylated. This has two implications. First, the function of Prmt1 appears to be nonredundant, since other cellular enzymes compensate for no more than a small part of the lost Prmt1 activity. Second, as previously observed with nucleolin and fibrillarin (18, 19), most potential substrates in normal cells appear to be blocked by prior methylation. Our analysis does not exclude the possibility that individual substrates are present in a hypomethylated state in ES cells or that the methylation status may change in response to different physiological conditions. Hypomethylated proteins may also exist only transiently, for example, during a specific step in a biochemical process. However, this latter possibility would require an arginine demethylase, an activity that has not yet been identified in mammalian cells. Experiments to study potential dynamic changes in protein methylation are in progress.
In summary, this report describes the first mutation in a mammalian arginine methyltransferase. These enzymes have been implicated in a wide variety of cellular processes, including cell proliferation, signal transduction, and protein trafficking. The availability of Prmt1-deficient cells will assist efforts to identify physiological substrates and to understand the function of the enzyme in normal cellular metabolism.
| |
ACKNOWLEDGMENTS |
|---|
We thank Harvey Herschman for the gift of anti-Prmt1 antibody, Abudi Nashabi for technical assistance, Eric Howard for measurements of protein methylarginine content, and Lucy Rowe, Mary Barter, and Lois Maltais of The Jackson Laboratory for assistance with gene mapping and nomenclature.
This work was supported by Public Health Service grants (R01HG00684, R01GM51201, and R01RR13166 to H.E.R.) and by a grant from the Kleberg Foundation. Additional support was provided by an NCI Cancer Center Support Grant (P30CA42014) to the Vanderbilt-Ingram Cancer Center. M.J.R. was supported by a Medical Scientist Training Grant (5T32-GM07347).
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Department of Microbiology and Immunology, Room AA4210 MCN, Vanderbilt University School of Medicine, 1161 21st Ave. South, Nashville, TN 37232-2363. Phone: (615) 343-1379. Fax: (615) 343-7392. E-mail: ruleye{at}ctrvax.vanderbilt.edu.
Present address: Department of Microbiology, University of
Washington, Seattle, WA 98195.
Present address: Department of Medicine, Division of
Rheumatology, Vanderbilt University School of Medicine, Nashville,
TN 37232-2363.
§ Present address: Department of Emergency Medicine, Carolinas Medical Center, Charlotte, NC 28232-2861.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abramovich, C., B. Yakobson, J. Chebath, and M. Revel. 1997. A protein-ginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J. 16:260-266[CrossRef][Medline]. |
| 2. |
Altschul, S. F.,
T. L. Madden,
A. A. Schaffer,
J. Zhang,
Z. Zhang,
W. Miller, and D. J. Lipman.
1997.
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
Nucleic Acids Res.
25:3389-3402 |
| 3. | Byvoet, P., G. R. Shepherd, J. M. Hardin, and B. J. Noland. 1972. The distribution and turnover of labeled methyl groups in histone fractions of cultured mammalian cells. Arch. Biochem. Biophys. 148:558-567[CrossRef][Medline]. |
| 4. |
Chen, D.,
H. Ma,
H. Hong,
S. S. Koh,
S. M. Huang,
B. T. Schurter,
D. W. Aswad, and M. R. Stallcup.
1999.
Regulation of transcription by a protein methyltransferase.
Science
284:2174-2177 |
| 5. | Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159[Medline]. |
| 6. |
Cimato, T. R.,
M. J. Ettinger,
X. Zhou, and J. M. Aletta.
1997.
Nerve growth factor-specific regulation of protein methylation during neuronal differentiation of PC12 cells.
J. Cell Biol.
138:1089-1103 |
| 7. | Copp, A. J. 1995. Death before birth: clues from gene knockouts and mutations. Trends Genet. 11:87-93[CrossRef][Medline]. |
| 8. |
DeGregori, J.,
A. Russ,
H. von Melchner,
H. Rayburn,
P. Priyaranjan,
N. A. Jenkins,
N. G. Copeland, and H. E. Ruley.
1994.
A murine homolog of the yeast RNA1 gene is required for postimplantation development.
Genes Dev.
8:265-276 |
| 9. | Fahrner, K., B. L. Hogan, and R. A. Flavell. 1987. Transcription of H-2 and Qa genes in embryonic and adult mice. EMBO J. 6:1265-1271[Medline]. |
| 10. | Feinberg, A. P., and B. Vogelstein. 1984. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 137:266-267[CrossRef][Medline]. |
| 11. | Gary, J. D., and S. Clarke. 1998. Protein arginine methyltransferases. Prog. Nucleic Acid Res. 61:65-133[Medline]. |
| 12. |
Gary, J. D.,
W. J. Lin,
M. C. Yang,
H. R. Herschman, and S. Clarke.
1996.
The predominant protein-arginine methyltransferase from Saccharomyces cerevisiae.
J. Biol. Chem.
271:12585-12594 |
| 13. | Henry, M. F., and P. A. Silver. 1996. A novel methyltransferase (Hmt1p) modifies poly(A)+-RNA-binding proteins. Mol. Cell. Biol. 16:3668-3678[Abstract]. |
| 14. | Hicks, G. G., E.-G. Shi, J. Chen, M. Roshon, D. Williamson, C. Scherer, and H. E. Ruley. 1995. Retrovirus gene traps. Methods Enzymol. 254:263-275[Medline]. |
| 15. | Kawasaki, E. S. 1990. Amplification of RNA, p. 21-27. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, Calif. |
| 16. | Kim, B. R., and K. H. Yang. 1991. Effects of sinefungin and 5'-deoxy-5'-S-isobutyl-adenosine on lipopolysaccharide-induced proliferation and protein N-methylation of arginyl residues in murine splenic lymphocytes. Toxicol. Lett. 59:109-116[CrossRef][Medline]. |
| 17. |
Lin, W. J.,
J. D. Gary,
M. C. Yang,
S. Clarke, and H. R. Herschman.
1996.
The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase.
J. Biol. Chem.
271:15034-15044 |
| 18. | Lischwe, M. A., R. G. Cook, Y. S. Ahn, L. C. Yeoman, and H. Busch. 1985. Clustering of glycine and NG,NG-dimethylarginine in nucleolar protein C23. Biochemistry 24:6025-6028[CrossRef][Medline]. |
| 19. |
Lischwe, M. A.,
R. L. Ochs,
R. Reddy,
R. G. Cook,
L. C. Yeoman,
E. M. Tan,
M. Reichlin, and H. Busch.
1985.
Purification and partial characterization of a nucleolar scleroderma antigen (Mr = 34,000; pI, 8.5) rich in NG,NG-dimethylarginine.
J. Biol. Chem.
260:14304-14310 |
| 20. | Liu, Q., and G. Dreyfuss. 1995. In vivo and in vitro arginine methylation of RNA-binding proteins. Mol. Cell. Biol. 15:2800-2808[Abstract]. |
| 21. |
Najbauer, J.,
B. A. Johnson,
A. L. Young, and D. W. Aswad.
1993.
Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins.
J. Biol. Chem.
268:10501-10509 |
| 22. | Paik, W. K., S. Kim, and H. W. Lee. 1972. Protein methylation during the development of rat brain. Biochem. Biophys. Res. Commun. 46:933-941[CrossRef][Medline]. |
| 23. | Pintucci, G., N. Quarto, and D. B. Rifkin. 1996. Methylation of high molecular weight fibroblast growth factor-2 determines post-translational increases in molecular weight and affects its intracellular distribution. Mol. Biol. Cell 7:1249-1258[Abstract]. |
| 24. | Rajpurohit, R., W. K. Paik, and S. Kim. 1994. Effect of enzymic methylation of heterogeneous ribonucleoprotein particle A1 on its nucleic-acid binding and controlled proteolysis. Biochem. J. 304:903-909. |
| 25. |
Reddy, S.,
H. Rayburn,
H. von Melchner, and H. E. Ruley.
1992.
Fluorescence-activated sorting of totipotent embryonic stem cells expressing developmentally regulated lacZ fusion genes.
Proc. Natl. Acad. Sci. USA
89:6721-6725 |
| 26. | Rowe, L. B., J. H. Nadeau, R. Turner, W. N. Frankel, V. A. Letts, J. T. Eppig, M. S. Ko, S. J. Thurston, and E. H. Birkenmeier. 1994. Maps from two interspecific backcross DNA panels available as a community genetic mapping resource. Mamm. Genome 5:253-274[CrossRef][Medline]. |
| 27. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 28. | Scherer, C. A., J. Chen, A. Nachabeh, N. Hopkins, and H. E. Ruley. 1996. Transcriptional specificity of the pluripotent embryonic stem cell. Cell Growth Differ. 7:1393-1401[Abstract]. |
| 29. | Scott, H. S., S. E. Antonarakis, M. D. Lalioti, C. Rossier, P. A. Silver, and M. F. Henry. 1998. Identification and characterization of two putative human arginine methyltransferases (HRMT1L1 and HRMT1L2). Genomics 48:330-340[CrossRef][Medline]. |
| 30. |
Shen, E. C.,
M. F. Henry,
V. H. Weiss,
S. R. Valentini,
P. A. Silver, and M. S. Lee.
1998.
Arginine methylation facilitates the nuclear export of hnRNP proteins.
Genes Dev.
12:679-691 |
| 31. |
Tang, J.,
A. Frankel,
R. J. Cook,
S. Kim,
W. K. Paik,
K. R. Williams,
S. Clarke, and H. R. Herschman.
2000.
PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells.
J. Biol. Chem.
275:7723-7730 |
| 32. |
Tang, J.,
J. D. Gary,
S. Clarke, and H. R. Herschman.
1998.
PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation.
J. Biol. Chem.
273:16935-16945 |
| 33. | Valentini, S. R., V. H. Weiss, and P. A. Silver. 1999. Arginine methylation and binding of Hrp1p to the efficiency element for mRNA 3'-end formation. RNA 5:272-280[Abstract]. |
| 34. |
Vanet, A.,
J. A. Plumbridge, and J. H. Alix.
1993.
Cotranscription of two genes necessary for ribosomal protein L11 methylation (prmA) and pantothenate transport (panF) in Escherichia coli K-12.
J. Bacteriol.
175:7178-7188 |
| 35. |
Williamson, D. J.,
J. DeGregori,
S. Banik-Maiti, and H. E. Ruley.
2000.
hnRNP C is required for postimplantation mouse development but is dispensable for cell viability.
Mol. Cell. Biol.
20:4094-4105 |
This article has been cited by other articles: